Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in FGFR-altered solid tumors
NCT03822117Phase 2Terminated
- Sponsor
- Incyte
- Start
- Oct 2019
- Primary completion
- Mar 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 11
01
Overview
Phase 2, open-label trial of pemigatinib in solid tumor malignancy (3 cohorts), sponsored by Incyte. Primary endpoint: Objective Response Rate up to 483 days. Started Oct 2019; status: terminated.
02
Drugs
pemigatinib
03
Conditions
solid tumor malignancy
Beyond the preview
Go deeper on NCT03822117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822117.